Restricted accessResearch articleFirst published online 2013-4
Vibrational Circular Dichroism (VCD) Chiral Assignment of Atropisomers: Application to γ-Aminobutyric Acid (GABA) Modulators Designed as Potential Anxiolytic Drugs
Atropisomers exist when axial chirality is present as a result of conformationally restricted rotation around a single bond. The interconversion rate of the individual atropisomers is critical to the assessment of chiral stability of a drug throughout scale-up, development, production, and storage as well as in vivo pharmacokinetics. We describe the application of vibrational circular dichroism spectroscopy coupled with quantum mechanics simulations to assign the absolute axial chirality and measure the racemization half-life of a series of potential anxiolytic drugs that act as γ-aminobutyric acid modulators.
LinG.ZhangJ.ChengJ.. “Overview of Chirality and Chiral Drugs”. In: LinG.ZhangJ.ChengJ., editors. Chiral Drugs: Chemistry and Biological Action. Hoboken, NJ: John Wiley and Sons, 2011. Pp. 3–28.
2.
WilliamsonM.P.WilliamsD.H.. “Structure Revision of Antibiotic Vancomycin. Use of Nuclear Overhauser Effect Difference Spectroscopy”. J. Am. Chem. Soc.1981. 103(22): 6580–6585.
3.
EveleighP.HulmeE.C.SchudtC.BirdsallN.J.M.. “The Existence of Stable Enantiomers of Telenzepine and Their Stereoselective Interaction with Muscarinic Receptor Subtypes”. Mol. Pharmacol.1989. 35(4): 477–483.
4.
ClaydenJ.MoranW.J.EdwardsP.J.LaplanteS.R.. “The Challenge of Atropisomerism in Drug Discovery”. Angew. Chem. Int. Ed.2009. 48(35): 6398–6402.
5.
LaplanteS.R.EdwardsP.J.FaderL.D.JakalianA.HuckeO.. “Revealing Atropisomer Axial Chirality in Drug Discovery”. ChemMed-Chem.2011. 6(3): 505–513.
6.
CrossW.HawkesG.E.KroemerR.T.LiedlC.R.LoertingT.NasserR.PritchardR.G.SteeleM.WatkinsonM.WhitingA.. “ The Structure, Modeling and Dynamics of Hindered 5,6-Diarylacenaphthenes”. J. Chem. Soc. Perkin Trans. B.2001. 4: 459–467.
7.
ZhouY.S.TayL.K.HughesD.DonahueS.. “Simulation of the Impact of Atropisomer Interconversion on Plasma Exposure of Atropisomers of an Endothelin Receptor Antagonist”. J. Clin. Pharmacol.2004. 44(7): 680–688.
AlhambraC.BeckerC.BlakeT.ChangA.DamewoodJ.R.DanielsT.DembofskyB.T.GurleyD.A.HallJ.E.HerzogK.J.HorchlerC.L.OhnmachtC.J.SchmiesingR.J.DudleyA.RibadeneiraM.D.KnappenbergerK.S.MaciagC.SteinM.M.ChopraM.LiuX.F.ChristianE.P.ArrizaJ.L.ChapdelaineM.J.. “Development and SAR of Functionally Selective Allosteric Modulators of GABAA Receptors”. Bioorg. Med. Chem.2011. 19(9): 2927–2938.
10.
NafieL.A.DukorR.K.. “Applications of Vibrational Optical Activity in the Pharmaceutical Industry”. In: PivonkaD.E.ChalmersJ.M.GriffithsP.R., editors. Application of Vibrational Spectroscopy in Pharmaceutical Research and Development. West Sussex, Chichester, UK: John Wiley and Sons, 2007. Pp. 129–154.
11.
StephensP.J.. “Theory of Vibrational Circular Dichroism”. J. Phys. Chem.1995. 89(5): 748–752.
12.
RaukA.. “Vibrational Circular Dichroism Intensities: Ab Initio Calculations. Understanding Chemical Reactivity”. In: MezeyP.G., editor. New Developments in Molecular Chirality. Dordrecht, the Netherlands: Kluwer Academic Publishers, 1991. Pp. 57–92.
13.
NafieL.A.FreedmanT.B.. “Vibronic Coupling Theory of Infrared Vibrational Transitions”. J. Chem. Phys.1983. 78(12): 7108–7116.
14.
CrawfordT.D.. “Ab Initio Calculation of Molecular Chiroptical Properties”. Theor. Chem. Acc.2000. 115(4): 227–245.
